Study Identifies New Combination Therapy for Esophageal Adenocarcinoma

Share this content:

(ChemotherapyAdvisor) – A large, multinational group of researchers, including those at M.D. Anderson Cancer Center, Houston, TX, published a study identifying a novel rationale for combination therapy against esophageal adenocarcinoma (EAC).

Mechanisms of oncogenesis for EAC — the most prevalent esophageal cancer type in the United States — were the subject of the study, which was entitled “The Crosstalk of mTOR/S6K1 and Hedgehog Pathways” and published in the March 20 issue of Cancer Cell. The TNF-α/mTOR pathway and aberrant activation of Gli1, a downstream effector of the Hedgehog (HH) pathway, are known oncogenic mechanisms that mediate the development of EAC.

The FDA has approved the mTOR inhibitor RAD-001 (Afinitor) and the Hedgehog inhibitor GDC-0449 (Erivedge) for use in other types of cancer. In this study, the combination of these two drugs significantly reduced the tumor burden by 90% in a mouse model of EAC, while the mTOR inhibitor RAD-001 alone had virtually no effect.

“In this study, we found that an activated mTOR/S6K1 pathway promotes Gli1 transcriptional activity and oncogenic function through S6K1-mediated Gli1 phosphorylation at Ser84, which releases Gli1 from its endogenous inhibitor, SuFu,” the authors wrote. “Moreover, elimination of S6K1 activation by an mTOR pathway inhibitor enhances the killing effects of the HH pathway inhibitor. Together, our results established a crosstalk between the mTOR/S6K1 and HH pathways, which provides a mechanism for SMO-independent Gli1 activation and also a rationale for combination therapy for EAC.”

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs